[Intraocular inflammation in multiple sclerosis].

Ophthalmologe

Universitäts-Augenklinik, Charité, Uveitis Zentrum Campus Virchow Klinikum - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Deutschland.

Published: June 2018

Multiple sclerosis (MS) is a chronic inflammatory disorder of the brain and the spinal cord occurring mostly in young adults and is associated with temporary or permanent neurological deficits. An association between uveitis and MS has been recognized for a long time. Current data indicate an approximately 10 times higher prevalence of uveitis in patients with MS compared to the general population. In particular, MS is associated with intermediate uveitis and typically with concomitant retinal vasculitis. The treatment of uveitis should not only take the severity of intraocular inflammation into account but a coordination of the active agents must also consider the neurological manifestations. Since uveitis and MS are pathogenetically based on an immune-mediated genesis, immunomodulatory treatment approaches are dominant but it is important to bear in mind that tumor necrosis factor(TNF)-alpha blocking agents may worsen MS.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00347-018-0673-5DOI Listing

Publication Analysis

Top Keywords

uveitis
5
[intraocular inflammation
4
inflammation multiple
4
multiple sclerosis]
4
sclerosis] multiple
4
multiple sclerosis
4
sclerosis a chronic
4
a chronic inflammatory
4
inflammatory disorder
4
disorder brain
4

Similar Publications

Background: Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.

View Article and Find Full Text PDF

Background And Objectives: Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients.

Methods: This single-centre retrospective cohort study included patients previously treated for nAMD who switched to faricimab between November 2022 and March 2024.

View Article and Find Full Text PDF

Uveitis in juvenile idiopathic arthritis: when to stop adalimumab?

Lancet

January 2025

Department of Ophthalmology, St Franziskus Hospital, Muenster, Germany; Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany.

View Article and Find Full Text PDF

Conventional treatments for autoimmune uveitis, such as corticosteroids and systemic immunosuppressants, often result in adverse side effects, prompting the need for therapies targeting specific molecular pathways. This study investigates the effects of Arctiin, known for its diverse biological properties, on experimental autoimmune uveitis (EAU) through its action on Th17 cells and the JAK/STAT signaling pathway. Our findings reveal that Arctiin significantly alleviates EAU by reducing clinical scores, inflammatory cell infiltration, and levels of inflammatory cytokines like IL-17 and TNF-α in the eye.

View Article and Find Full Text PDF

Purpose: To present the case of a young patient with BRAF V600E-mutant cutaneous melanoma who developed bilateral choroidal metastases complicated by neovascular glaucoma (NVG) in both eyes following the interruption of nivolumab therapy.

Methods: A 28-year-old female with primary cutaneous melanoma of the left hand underwent surgical resection and adjuvant nivolumab. Immunotherapy was discontinued due to immune-related acute interstitial nephritis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!